Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tue

Dimensional Fund Advisors LP boosted its holdings in Xencor, Inc. (NASDAQ: XNCR) by 3.6% during the

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises t

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises th

Cantor Fitzgerald analyst Steve Seedhouse maintains Xencor (NASDAQ:XNCR) with a Overweight and ra

Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co

Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintain

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharma

U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average

Details of the Proffered Paper Oral PresentationTitle: Phase 1 results of XmAb819, a novel ENPP3 x C

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co

Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets ac

Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov

Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcrip

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co

Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its 200-day moving average during trading

Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrade

JP Morgan analyst Brian Cheng downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowe

Pre-Market Stock Futures: After a volatile start to the week, futures are trading lower on Tuesday.

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has been given a consensus recommendation of "Moderate

Xencor, Inc. (NASDAQ: XNCR - Get Free Report)'s stock price gapped down before the market opened on

On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied

Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028

Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the pri

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus

Why Xencor Stock's current weakness may persist and why rallies ahead are unlikely to sustain.

Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the pri

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibod

Truist Securities analyst Gregory Renza initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rat

JP Morgan analyst Brian Cheng maintains Xencor (NASDAQ:XNCR) with a Overweight and lowers the pri

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises t

Cantor Fitzgerald analyst Steve Seedhouse maintains Xencor (NASDAQ:XNCR) with a Overweight and ra

Barclays analyst Etzer Darout upgrades Xencor (NASDAQ:XNCR) from Underweight to Overweight and ra

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises t

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall r

-- Management to host webcast and conference call on Friday, October 24, 2025 --Xencor, Inc. (NASDAQ

Cantor Fitzgerald analyst Steve Seedhouse assumes Xencor (NASDAQ:XNCR) with a Overweight rating a

B of A Securities analyst Alec Stranahan downgrades Xencor (NASDAQ:XNCR) from Buy to Neutral and